Aadi Bioscience (FRA:3350) EV-to-EBIT : 0.58 (As of May. 18, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Aadi Bioscience's Enterprise Value is €-37.00 Mil. Aadi Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-63.39 Mil. Therefore, Aadi Bioscience's EV-to-EBIT for today is 0.58.

The historical rank and industry rank for Aadi Bioscience's EV-to-EBIT or its related term are showing as below:

FRA:3350' s EV-to-EBIT Range Over the Past 10 Years
Min: -684.43 Med: -1.09 Max: 1.03
Current: 0.59

During the past 4 years, the highest EV-to-EBIT of Aadi Bioscience was 1.03. The lowest was -684.43. And the median was -1.09.

FRA:3350's EV-to-EBIT is ranked better than
74.88% of 426 companies
in the Biotechnology industry
Industry Median: 10.22 vs FRA:3350: 0.59

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Aadi Bioscience's Enterprise Value for the quarter that ended in Mar. 2024 was €-26.61 Mil. Aadi Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-63.39 Mil. Aadi Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 238.23%.

Aadi Bioscience EV-to-EBIT Historical Data

The historical data trend for Aadi Bioscience's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience EV-to-EBIT Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-3.26

-2.37

0.88

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial										-0.44	-0.56	-0.01	0.88	0.43

Competitive Comparison of Aadi Bioscience's EV-to-EBIT

For the Biotechnology subindustry, Aadi Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aadi Bioscience's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's EV-to-EBIT falls into.

Aadi Bioscience EV-to-EBIT Calculation

Aadi Bioscience's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-37.000	/	-63.394
	=	0.58

Aadi Bioscience's current Enterprise Value is €-37.00 Mil.
Aadi Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-63.39 Mil.

Aadi Bioscience (FRA:3350) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Aadi Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-63.394	/	-26.610844
	=	238.23 %

Aadi Bioscience's Enterprise Value for the quarter that ended in Mar. 2024 was €-26.61 Mil.
Aadi Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-63.39 Mil.

Aadi Bioscience EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience (FRA:3350) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

AADI:USA 3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines